Feldschuh Michael Richard

CEO Feldschuh buys 1,000 DXR shares at $9.07; stock down 35.9% from 52-week high, company unprofitable

CEO Michael Richard Feldschuh purchased 1,000 shares at $9.07 on 2026-04-08, increasing his holdings to 213.7K shares. The purchase occurs amid substantial recent weakness: the stock is -35.9% from its 52-week high and down 16.9% over the past 30 days. Notably, his prior trades at DXR show a strong timing pattern—4 of 5 prior buys achieved positive 90-day returns, with the most recent two purchases (on 2025-04-04 and 2025-03-10) followed by +24.6% and +20.4% gains respectively. However, the company's fundamentals remain challenged: DAXOR is unprofitable (net income of $-4.2M in the latest quarter), revenues have contracted 8.4% year-over-year, and the market cap sits at only $39.7M. This buy occurs in a financially distressed context, though the insider's historical execution at this ticker suggests disciplined entry timing.

CEO Michael Richard Feldschuh purchases 2,063 shares at $7.89; stock down 25.0% from 52-week high.

CEO Michael Richard Feldschuh purchased 2,063 shares on 2025-04-04 at $7.89, bringing holdings to 212,694 shares. The purchase occurs as the stock trades at $7.45, down 25.0% from its 52-week high of $9.94 and down 6.9% over the preceding 30 days. At Daxor, Feldschuh's timing pattern shows 3 of 4 prior DXR buys were well-timed at the 90-day mark, with measured outcomes ranging from -12.6% to +23.1%—mixed results with notable downside from the December 2024 purchase. Fundamentally, the company reported negative net income of $-4.2M in its latest quarter, annual revenue decline of -8.4%, and operates at a depressed market cap of $31.3M. The CEO's cross-ticker track record shows an average 90-day return of +3.9% across 8 prior buys elsewhere, but this purchase occurs within a context of operational losses and sustained stock weakness at this specific ticker.

CEO Feldschuh purchased 1,000 DXR shares at $8.13; stock -18.5% from 52-week high on $34.0M market cap, unprofitable fundamentals.

Michael Richard Feldschuh, Chief Executive Officer of Daxor Corp, purchased 1,000 shares at $8.13 on 2024-03-26, increasing his holdings to 210,631 shares. The transaction occurred while the stock trades at $8.10, currently -18.5% from its 52-week high of $9.94, and the company faces structural headwinds: revenue declined 8.4% year-over-year, with latest quarterly revenue of $340.9K and a full-year net loss of $-4.2M. His same-ticker history at DXR shows mixed outcomes (3 of 4 prior measurable 90-day returns were positive, most recently +8.3% following a March 2024 buy), though his cross-ticker track record across all holdings demonstrates modest success with a 66.67% 90-day win rate and +2.0% average 90-day return. The small position size (+1,000 shares, +0.5% of holdings) amid the company's unprofitable operating environment and recent stock weakness limits the signal strength of this transaction.

CEO Michael Richard Feldschuh buys 647 DXR shares at $8.15; 3 of 4 prior buys at this ticker were well-timed 90-day outcomes.

Feldschuh purchased 647 shares of Daxor at $8.15 on 2024-03-19, increasing his holdings by 0.3% to 209.6K shares. His prior open-market trading history across all tickers shows 7 buys with a 66.67% 90-day win rate, and at DXR specifically, 3 of his 4 measurable prior purchases posted positive 90-day returns, suggesting a pattern of reasonably-timed entry points at this company. However, the company's fundamentals present a headwind: it reported negative net income of $-4.2M, annual revenue contracted 8.4% year-over-year, and quarterly revenue of $340.9K remains modest relative to a $35.2M market cap. The most recent comparable buy at DXR (2024-12-06) yielded a -12.6% 90-day return, breaking the prior pattern and underscoring execution risk in a structurally weak operating environment.

CEO Michael Feldschuh purchases 3,360 DXR shares at $7.68; stock down 21.6% from 52-week high amid unprofitability

CEO Michael Feldschuh bought 3,360 shares at $7.68, increasing his holdings to 210.9K shares (+1.6%), at a time when DAXOR has declined 21.6% from its 52-week high of $9.94 and faces fundamental headwinds: annual revenue fell 8.4% year-over-year, and the company posted a $-4.2M net loss on $340.9K quarterly revenue. His cross-ticker track record shows a 71.43% 90-day win rate with +3.9% average 90-day return across 7 prior buys, but at this specific ticker (DXR), his timing has been mixed—while 4 of 5 prior trades showed positive 90-day returns, his most recent buy on 2024-12-06 declined 12.6% over 90 days. The current trade coincides with a 30-day rally of +4.4%, but comes in the context of ongoing operational losses and structural revenue contraction, making this purchase noteworthy for potential scrutiny of whether the CEO's commitment aligns with market skepticism.

CEO Feldschuh buys 45,000 shares of DXR; holdings jump 27.7% to 207,492 shares; 5 of 5 prior DXR buys well-timed at 90d mark.

Michael Richard Feldschuh, Chief Executive Officer of Daxor Corp, purchased 45,000 shares on 2024-12-06, increasing his holdings by 27.7% from 162,492 to 207,492 shares. This is a substantial concentration increase in a company with a market cap of $37.4M that posted a net income of $-4.2M in its most recent full fiscal year and reported revenue of only $340.9K in the latest quarter. Of particular note, Feldschuh's prior five open-market purchases at DXR all posted positive 90-day returns (ranging from +1.2% to +23.1%), indicating a consistent pattern of well-timed entry points at this specific ticker. The current stock price of $8.91 is -11.2% from the 52-week high and has declined -5.9% over the past 30 days, creating a window where the CEO is accumulating despite recent weakness and fundamental unprofitability.